Pfizer will now lead all development and commercialization activities in Mainland China, Hong Kong, Macau, and Singapore LianBio will receive...
REHOVOT, Israel and HOBOKEN, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated...
Results from Planned Interim Analysis of First 50 Percent of Participants Expected Second Quarter 2023 Topline Results Expected Fourth Quarter...
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors DUBLIN,...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19, 2022 –...
MW005 shown to be safe and well-tolerated Data provides clinical efficacy proof-of-concept based on complete clearance of target lesions YAVNE,...
WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to...
In MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints...
CALGARY, Alberta, Dec. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for...
The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated...
Chair of the Board of Directors, Sean P. Nolan, appointed Chief Executive Officer Board Director, Sukumar Nagendran, M.D., appointed President...
CHICAGO and TORONTO, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF),...
The exponential growth of attack surfaces has led many to prioritize security beyond the firewallWALTHAM, Mass., Dec. 15, 2022 (GLOBE...
ANNOUNCEMENT NO. 233 14 December 2022 Management change Steen Søndergaard has announced that he wants to resign from his position...
MINNEAPOLIS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the...
The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada, Dec. 13, 2022...
– US board-certified medical oncologist with extensive global clinical and regulatory experience advancing oncology medicines from early development stages through...
GFH009 is First CDK9 Inhibitor Monotherapy to Achieve Compete Response in Acute Myeloid Leukemia Anticancer Effects Observed Across Multiple Dose...
SAB brings extensive expertise in precision oncology, drug development, and early phase clinical trialsNEW HAVEN, Conn., Dec. 13, 2022 (GLOBE...